Evidence map›Paper›PMID 33838922›Full record

Observational studyPathology2021

SARS-CoV-2 viral load dynamics and real-time RT-PCR cycle threshold interpretation in symptomatic non-hospitalised individuals in New Zealand: a multicentre cross sectional observational study.

Andrew Fox-Lewis, Shivani Fox-Lewis, Jenna Beaumont, Dragana Drinković, Jay Harrower, Kevin Howe, Catherine Jackson, Fahimeh Rahnama, Blair Shilton, Helen Qiao and 6 more

Open access · bronzeAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Andrew Fox-LewisMicrobiology Department, LabPLUS, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand.
Shivani Fox-LewisVirology-Immunology Department, LabPLUS, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand. Electronic address: afoxlewis@gmail.com.
Jenna BeaumontMicrobiology Department, Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand.
Dragana DrinkovićMicrobiology Department, North Shore Hospital, Waitematā District Health Board, Auckland, New Zealand.
Jay HarrowerAuckland Regional Public Health Service, Auckland District Health Board, Auckland, New Zealand.
Kevin HoweAuckland Regional Public Health Service, Auckland District Health Board, Auckland, New Zealand.
Catherine JacksonNga Tai Ora Public Health Northland, Northland District Health Board, Whangarei, New Zealand.
Fahimeh RahnamaVirology-Immunology Department, LabPLUS, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand.
Blair ShiltonLabtests, Auckland, New Zealand.
Helen QiaoMicrobiology Department, Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand.
Kevin K SmithMicrobiology Department, North Shore Hospital, Waitematā District Health Board, Auckland, New Zealand.
Susan C MorpethMicrobiology Department, Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand.
Susan TaylorMicrobiology Department, Middlemore Hospital, Counties Manukau District Health Board, Auckland, New Zealand.
Matthew BlakistonMicrobiology Department, LabPLUS, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand; Labtests, Auckland, New Zealand.
Sally RobertsMicrobiology Department, LabPLUS, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand.
Gary McAuliffeVirology-Immunology Department, LabPLUS, Auckland City Hospital, Auckland District Health Board, Auckland, New Zealand; Labtests, Auckland, New Zealand.
Auckland City Hospital · NZMiddlemore Hospital · NZAuckland District Health Board · NZNorth Shore Hospital · NZNorthland District Health Board · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a multicentre cross sectional observational study of laboratory, public health and hospitalisation data for PCR-confirmed COVID-19 cases within the New Zealand Northern Region, between 12 February and 8 June 2020. The aim of this study was to describe population level SARS-CoV-2 upper respiratory tract (URT) viral load dynamics by stratifying positivity rates and polymerase chain reaction (PCR) cycle threshold (Ct) values of URT samples from COVID-19 cases by days since symptom onset, and to explore utility of Ct values in determining length of time post-infection and thus potential infectivity. Of 123,124 samples tested for SARS-CoV-2 by PCR, 579 samples (407 positive and 172 negative) from 368 symptomatic non-hospitalised individuals with PCR-confirmed infection were included. Sample positivity rate was 61.5% (8/13) for pre-symptomatic samples, rising to 93.2% (317/340) for samples collected during the purported symptomatic infectious period (days 0-10 post-symptom onset), and dropping to 36.3% (82/226) for post-infectious period samples (day 11 onwards). URT viral load peaked shortly after symptom onset, with median Ct values ranging 20.00-29.99 until 15 days post-symptom onset, and >30.00 after this time. Of samples with a Ct value of <20.00, 96.1% were collected during the symptomatic infectious period. However, of samples with a Ct value ≥30.00 and ≥35.00, 46.9% and 18.5%, respectively, were also collected during the symptomatic infectious period. The findings of this study indicate that at or soon after symptom onset represents the optimum time to test for SARS-CoV-2 in the URT, with median Ct values suggesting the useful testing window extends until around 15 days post-symptom onset. In asymptomatic individuals or those with unknown dates of symptom onset, Ct values <20.00 imply recent onset/potential infectivity, but Ct values ≥30.00 or ≥35.00 do not exclude recent onset/potential infectivity. Individual sample Ct values should not be used as an absolute marker of length of time post-infection or to exclude infectivity where date of symptom onset is unavailable.

Indexed as

SARS-CoV-2Viral LoadAdolescentAdultAgedAged, 80 and overChildChild, PreschoolCOVID-19COVID-19 TestingCross-Sectional StudiesFemaleHumansMaleMiddle AgedNew ZealandCOVID-19cycle thresholdNew ZealandPCRSARS-CoV-2

Identifiers

PMID33838922
PMCPMC7980174
OpenAlexW3137020411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.